Navigation Links
Medivation Announces Participation in 29th Annual J.P. Morgan Healthcare Conference
Date:1/3/2011

SAN FRANCISCO, Jan. 3, 2011 /PRNewswire/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, at 10:30 a.m. Pacific Time at the Westin St. Francis Hotel in San Francisco.

Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.

Live audio webcasts of the presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at www.medivation.com. A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Pfizer and Astellas, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at www.medivation.com.


'/>"/>
SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Fourth Quarter and Year-End 2009 Financial Results Teleconference and Webcast On March 15, 2010
2. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
3. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimers Disease
4. Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
8. Medivation Announces Pricing of Public Offering
9. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
10. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused on ... of tumor cells in the bloodstream, today announced that ... support application powered by CollabRx, Inc. , Available ... Therapy Finder will provide breast cancer patients and their ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Copper,s days are numbered, and a new study ... the ubiquitous metal in smart phones, tablet computers, and ... who are seeking smaller, faster devices. As ... size, so do the copper pathways that transport electricity ...
... Interleukin Genetics, Inc. (OTCQB: ILIU) today announced financial and ... Total revenue for the three months ended September ... period in the prior year. The increase was attributable to ... expenses were $325,000 for the three months ended September 30, ...
... Nov. 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), ... prevent and fight Human Immunodeficiency Virus (HIV) infections, today ... September 30, 2011. GeoVax reported a net ... months ended September 30, 2011, compared to $644,666 ($0.04 ...
Cached Biology Technology:Researching graphene nanoelectronics for a post-silicon world 2Researching graphene nanoelectronics for a post-silicon world 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5
(Date:4/23/2014)... is a newly coined term for novels and films which ... University of Copenhagen shows how these fictions serve as a ... of climate change and imagine other living conditions. , ... in the atmosphere; it is also a cultural phenomenon in ... and the films we see. And there are so many ...
(Date:4/23/2014)... disease is the first cause of dementia and affects ... cure has yet been found. One of the reasons ... cellular mechanisms which cause alterations in nerve transmissions and ... the disease., Researchers from the Institute of Neuroscience at ... mechanism involved in memory consolidation and were able to ...
(Date:4/23/2014)... social mammals, ravens form different types of social relationships ... they also form strict dominance relations. From a cognitive ... key ability in daily social life ("knowing who is ... members have with each other sets the stage for ... of this study have been published in the scientific ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3Loss of memory in Alzheimer's mice models reversed through gene therapy 2Ravens understand the relations among others 2
... sleuthing system they developed to probe how cells manage ... common but hard-to-see sugar switches are partly in control. ... abundant and potential targets of manipulation by drugs, the ... for a number of diseases, including cancer, the scientists ...
... , REDWOOD CITY, Calif. , ... has selected DigitalPersona, Inc., a leader in fingerprint identity and ... Justice Information System (CJIS) mandates. Located in Central Florida , ... who serve more than 28,000 residents. The City chose DigitalPersona ® ...
... 2010 The Translational Genomics Research Institute (TGen) today ... agreement with the Van Andel Research Institute (VARI) that ... TGen expects the agreement to create a ... and treatments for patient benefit. ...
Cached Biology News:Sweet! -- sugar plays key role in cell division 2City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance 2City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance 3City of Winter Park Looks to DigitalPersona Software for Stronger Security and CJIS Compliance 4TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3